| Cas No.: | 111358-88-4 |
| Chemical Name: | Lestaurtinib |
| Synonyms: | Lestaurtinib;Lestaurtinib ( CEP-701, KT 5555, SP 924);CEP-701;CEP-701 hydrate;KT 5555;SP 924;UNII-DO989GC5D1;(15S,16S,18R)-16-HYDROXY-16-(HYDROXYMETHYL)-15-METHYL-28-OXA-4,14,19-TRIAZAOCTACYCLO[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]OCTACOSA-1(26),2(6),7(27),8,10,12,20,22,24-NONAEN-3-ONE;9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one,2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, [9S-(9a,10b,12a)]-;A 154475.0;CEP 701;SPM-924;Apalutamide;KT-5555 hydrate;Lestaurtinib hydrate |
| SMILES: | O=C1NCC(C2=C3N([C@]4(C)[C@](CO)(O)C[C@@]5([H])O4)C6=CC=CC=C62)=C1C7=C3N5C8=CC=CC=C78 |
| Formula: | C26H21N3O4 |
| M.Wt: | 439.46 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | Lestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3 and TrkA with IC50s of 0.9, 3 and less than 25 nM, respectively. |
| Target: | JAK2:0.9 nM (IC50) TrkA:25 nM (IC50) FLT3:3 nM (IC50) |
| References: | [1]. Miknyoczki SJ, et al. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci. 1999 Jun 30;880:252-62. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|
| 2018-0101 |
|